Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Accepts Novartis Vaccines' sBLA to Expand Indication of Menveo(R) to Children 2-10 Years of Age
FDA Accepts Novartis Vaccines' sBLA to Expand Indication of Menveo(R) to Children 2-10 Years of Age
FDA Accepts Novartis Vaccines' sBLA to Expand Indication of Menveo(R) to Children 2-10 Years of Age
Submitted by
admin
on May 8, 2010 - 10:07am
Source:
Yahoo/MarketWire
News Tags:
Novartis
bacterial meningitis
Menveo
Headline:
FDA Accepts Novartis Vaccines' sBLA to Expand Indication of Menveo(R) to Children 2-10 Years of Age
Do Not Allow Advertisers to Use My Personal information
